Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the national biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings like the American Society of Clinical Oncology and broke news about the industry’s top companies, including Amgen, Genentech, and Biogen Idec. His stories appeared in The New York Times, Los Angeles Times, and International Herald Tribune. From 2001 to 2006, his passionate coverage of the biotechnology industry won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service.
Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke runs marathons, climbs mountains and roots for the Green Bay Packers.
-
This was the week that a little biotech company in Bothell that few of the locals have ever heard of, burst onto the national stage.
—Bothell, WA-based Alder Biopharmaceuticals had its... Read more »
-
[Corrected: 7:26 am Pacific, 11/12/09] San Diego-based Altair Therapeutics, a company developing inhalable drugs to block inflammatory proteins involved in asthma and other respiratory diseases, has closed on the... Read more »
-
Cambridge, MA-based Aileron Therapeutics has bet the company on the idea that it has discovered a whole new class of drugs that, like RNA interference, can hit targets in the body... Read more »
-
Alder Biopharmaceuticals keeps such a low profile that even after five years in business, few people in Seattle biotech know who they are. That changed yesterday as the private Bothell, WA-based... Read more »
-
Vertex Pharmaceuticals, the Cambridge, MA-based developer of treatments for hepatitis C, said today that investors who hold about $109 million worth of debt securities have converted those holdings into equity stakes.... Read more »
-
The Institute for Systems Biology, a Seattle-based nonprofit research center, said today it has secured an $8 million grant from the National Institutes of Health as part of The Cancer Genome... Read more »
-
[Update: 10:42 am Eastern, 11/10/09] Cambridge, MA-based Ironwood Pharmaceuticals, the developer of a treatment for chronic constipation and irritable bowel syndrome, has formed a partnership with Japan-based Astellas Pharma... Read more »
-
Alder Biopharmaceuticals has just struck one of the biggest biotech partnerships of the year, both in the Seattle area and nationally. The Bothell, WA-based developer of faster and cheaper technology for... Read more »
-
Who are the innovators who will help keep the San Diego region’s life sciences sector vibrant in the years to come? Which of the emerging ideas here will help transform the... Read more »
-
BioVex, the Woburn, MA-based company aspiring to create the first FDA-approved cancer-killing virus, has raised an additional $30 million in private financing to finish off a pivotal clinical trial needed... Read more »
-
Prostate cancer has been one of the hot fields for new biotech drug development this year, and now Cambridge, MA-based Tokai Pharmaceuticals is getting into the game with a drug that... Read more »
-
Kineta, the Seattle-based developer of drugs for autoimmune diseases, has won about half of a $13 million federal contract awarded to the University of Washington to create new compounds which... Read more »
-
Helicos Biosciences (NASDAQ: HLCS) said today that it has decided to call off discussions that could lead to a sale of the company, because of its “improving standalone prospects and... Read more »
-
Dendreon (NASDAQ: DNDN), the Seattle-based developer of a new treatment to stimulate the immune system against prostate cancer, said today in its quarterly financial report that it ended September with... Read more »
-
ZymoGenetics started really playing hardball with King Pharmaceuticals in August, and now a high-and-tight fastball has come right back at the Seattle biotech company.
The projectile in question is a... Read more »
-
Bothell, WA-based Verathon, which markets a simple ultrasound technology to help doctors diagnose common bladder disorders, has been acquired by Sarasota, FL-based Roper Industries in a pair of transactions worth a... Read more »
-
Concert Pharmaceuticals, the Lexington, MA-based company that chemically modifies existing drugs to make them more attractive, has started human testing of an HIV medication which it hopes will help GlaxoSmithKline wrestle... Read more »
-
Ion Torrent Systems, a company advised by Harvard University genomics pioneer George Church, has raised $23 million in new capital to develop what it calls on its website “groundbreaking... Read more »
-
RXi Pharmaceuticals (NASDAQ: RXII), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently... Read more »
-
Gloucester Pharmaceuticals has won clearance to start selling its first cancer drug in the U.S.
The Cambridge, MA-based biotech company said today it has gotten the green light from the FDA... Read more »
